PAHT - When the patent for the drug with the highest NHS expenditure expires - @QualityFirstPAH

Aim: Switch all patients from the originator of Adalimumab (Humira) to Adalimumab Biosimilar (Imraldi / Amgevita).

Goal set by NHS England: 90% of all new patients switched within 3 months and 80%of all existing patients to be switched to a biosimilar within 12 months.

PAHT-Rheumatology---Biosimilars---Sep-2019.